var data={"title":"Klippel-Trenaunay syndrome: Clinical manifestations, diagnosis, and management","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Klippel-Trenaunay syndrome: Clinical manifestations, diagnosis, and management</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/contributors\" class=\"contributor contributor_credentials\">Ilona J Frieden, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/contributors\" class=\"contributor contributor_credentials\">Derek H Chu, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/contributors\" class=\"contributor contributor_credentials\">Moise L Levy, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 12, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H738068296\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Klippel-Trenaunay syndrome (KTS) is a complex congenital disorder that historically has been defined as the triad of capillary malformation, venous malformation, and limb overgrowth [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/1\" class=\"abstract_t\">1</a>]. In the past, a number of different conditions have been lumped together under the moniker of KTS, including Parkes Weber syndrome and diffuse capillary malformation with overgrowth (DCMO) [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/2\" class=\"abstract_t\">2</a>], but clearer descriptions of phenotype and emerging genotypic studies have helped in distinguishing these disorders. In the International Society for the Study of Vascular Anomalies' 2014 classification of vascular anomalies, KTS is defined as a syndrome with capillary and venous malformations as well as limb overgrowth with or without lymphatic malformation [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/1\" class=\"abstract_t\">1</a>]. Most cases of KTS analyzed genomically were found to be caused by mosaic-activating mutations in the <em>PIK3CA</em> gene. Some authors have proposed that KTS be labeled not as a distinct diagnostic entity but as a member of the <em>PIK3CA</em>-related overgrowth spectrum (PROS) [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/3-5\" class=\"abstract_t\">3-5</a>].</p><p>Klippel-Trenaunay syndrome will be discussed in this topic. The diagnosis and management of other capillary malformations and related overgrowth syndromes are discussed separately. (See <a href=\"topic.htm?path=capillary-malformations-port-wine-stains-and-associated-syndromes\" class=\"medical medical_review\">&quot;Capillary malformations (port wine stains) and associated syndromes&quot;</a> and <a href=\"topic.htm?path=pten-hamartoma-tumor-syndrome-including-cowden-syndrome\" class=\"medical medical_review\">&quot;PTEN hamartoma tumor syndrome, including Cowden syndrome&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3425593432\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Klippel-Trenaunay syndrome (KTS) is rare. Its incidence and prevalence are not known. There is no apparent ethnic or gender predilection. </p><p class=\"headingAnchor\" id=\"H3968521269\"><span class=\"h1\">CLASSIFICATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Historically, experts have used a variety of broad definitions for Klippel-Trenaunay syndrome (KTS). The term &quot;Klippel-Trenaunay-Weber&quot; was once used to describe patients with features of KTS along with arteriovenous fistulas, when this in fact represented a distinct disorder now called Parkes Weber syndrome. </p><p>Some have defined KTS as the presence of any two of three cardinal features, including capillary malformation, soft tissue or bony hypertrophy, and varicose veins or venous malformations [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/6\" class=\"abstract_t\">6</a>]. We will use the 2014 classification of the International Society for the Study of Vascular Anomalies (ISSVA), which defines KTS as the combination of capillary malformation, venous malformation, and limb overgrowth, with or without lymphatic malformation [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/1\" class=\"abstract_t\">1</a>]. However, we acknowledge that many milder cases previously diagnosed as KTS without lymphatic involvement fit better under the diagnosis of diffuse capillary malformation with overgrowth (DCMO) [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H2839404764\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Klippel-Trenaunay syndrome (KTS) is, in most cases, a sporadic condition, although rare familial cases have been reported [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/7\" class=\"abstract_t\">7</a>]. Paradominant inheritance has been proposed to explain this occasional familial occurrence [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/8\" class=\"abstract_t\">8</a>]. While various genetic defects have been identified as possible causative factors for KTS, including overexpression of the angiogenic factor VG5Q and a de novo supernumerary ring chromosome 18 [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/9,10\" class=\"abstract_t\">9,10</a>], several studies indicate that most patients with KTS carry postzygotic somatic mutations in the phosphatidylinositol-4, 5-bisphospate 3-kinase, catalytic subunit alpha (<em>PIK3CA</em>) gene [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/4\" class=\"abstract_t\">4</a>]. </p><p>Gain-of-function mutations in <em>PIK3CA</em> lead to the activation of protein kinase B (AKT) and, ultimately, mammalian target of rapamycin (mTOR), with resultant cell proliferation and angiogenesis. Similar mutations have been discovered in entities such as congenital lipomatous overgrowth with vascular malformations, epidermal nevi, and skeletal anomalies (CLOVES) syndrome, fibro-adipose vascular anomaly (FAVA), and macrocephaly-capillary malformation (M-CM, MCAP) syndrome [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/4,11,12\" class=\"abstract_t\">4,11,12</a>]. </p><p>Although these syndromes may have unique features, possibly related to tissue-specific distribution, they may also show considerable clinical overlap. Moreover, some cases do not fit neatly into a single category or diagnosis. The term <em>PIK3CA</em>-related overgrowth spectrum (PROS) has thus been suggested to encompass these distinct yet overlapping conditions [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/13\" class=\"abstract_t\">13</a>]. (See <a href=\"topic.htm?path=vascular-lesions-in-the-newborn#H793097204\" class=\"medical medical_review\">&quot;Vascular lesions in the newborn&quot;, section on 'Vascular malformations associated with other anomalies'</a>.)</p><p class=\"headingAnchor\" id=\"H3383733452\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The combination of cutaneous capillary <span class=\"nowrap\">malformation/port-wine</span> stain, venous varicosities or malformation, and underlying soft tissue <span class=\"nowrap\">and/or</span> bone hypertrophy of the involved extremity, with or without lymphatic anomalies, represents the key clinical feature of Klippel-Trenaunay syndrome (KTS) (<a href=\"image.htm?imageKey=DERM%2F108288%7EDERM%2F108289%7EDERM%2F108290\" class=\"graphic graphic_picture graphicRef108288 graphicRef108289 graphicRef108290 \">picture 1A-C</a>). The severity of KTS likely reflects the timing of development in utero, as well as which components of the vasculature and other anatomic structures (eg, bone, muscle, skin, subcutis) are predominantly affected. </p><p class=\"headingAnchor\" id=\"H3037764232\"><span class=\"h2\">Capillary malformation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The cutaneous vascular stains (port-wine stains) of KTS are noted at birth and most commonly involve the lower extremity. Involvement of the ipsilateral or contralateral upper limb and extension to the adjacent truncal skin are not uncommon [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/14\" class=\"abstract_t\">14</a>]. Capillary stains can be classified as geographic or <span class=\"nowrap\">blotchy/segmental</span>. Geographic stains are usually dark-red or purple in color and have a sharply demarcated, irregular shape resembling that of a country or continent (<a href=\"image.htm?imageKey=DERM%2F108288%7EDERM%2F108289\" class=\"graphic graphic_picture graphicRef108288 graphicRef108289 \">picture 1A-B</a>). <span class=\"nowrap\">Blotchy/segmental</span> stains, on the other hand, have less distinct margins and are often large and confluent with lighter pink-red coloration. </p><p>In a retrospective study of 40 patients with KTS, 21 of 22 with geographic stains had definite or probable lymphatic disease, while 16 of 17 with blotchy stains had no evidence or only possible lymphatic malformation. In addition to predicting lymphatic involvement in KTS, geographic stains may also identify patients with a propensity for disease complications [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/15\" class=\"abstract_t\">15</a>]. (See <a href=\"topic.htm?path=capillary-malformations-port-wine-stains-and-associated-syndromes\" class=\"medical medical_review\">&quot;Capillary malformations (port wine stains) and associated syndromes&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3542307160\"><span class=\"h2\">Venous malformation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In KTS, the persistence of embryonic avalvular venous structures, most notably the lateral vein of the thigh (lateral marginal vein of Servelle) and sciatic vein, can result in dilated tortuous varicosities, with superficial ones being more often located over the anterolateral thigh and leg (<a href=\"image.htm?imageKey=DERM%2F108289\" class=\"graphic graphic_picture graphicRef108289 \">picture 1B</a>) [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/16\" class=\"abstract_t\">16</a>]. In addition to phlebectatic venous malformations, more &quot;cavernous&quot; venous malformations may also be present. If present in superficial soft tissues, these often present as soft, compressible, subcutaneous blue masses, with increased prominence in dependent positions. Venous malformations may be evident at birth or during infancy, but typically become more apparent during childhood.</p><p>Structural abnormalities of the deep venous system can also occur. These include venous hypoplasia or aplasia, aneurysm formation or dilatation, valvular incompetence, and compression from fibrotic bands or anomalous vasculature, with the popliteal and superficial femoral veins most commonly affected [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/6\" class=\"abstract_t\">6</a>]. Deeper venous anomalies may only be detected with imaging studies. (See <a href=\"#H1885598182\" class=\"local\">'Imaging studies'</a> below.)</p><p class=\"headingAnchor\" id=\"H3788216779\"><span class=\"h2\">Lymphatic malformation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lymphatic malformations in KTS may be microcystic, macrocystic, or mixed. Clinically, the disruption of the lymphatic system is frequently characterized by the presence of superficial vascular blebs or lymphangiectasias, resembling &quot;frog spawn,&quot; often but not exclusively located in the area of geographic stains (<a href=\"image.htm?imageKey=DERM%2F108289\" class=\"graphic graphic_picture graphicRef108289 \">picture 1B</a>). These lesions are at risk for chronic leakage of lymph or blood and secondary infection. </p><p>Additional features of lymphatic malformations include pseudoverrucous hyperplasia and lymphedema [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/16\" class=\"abstract_t\">16</a>]. When present, lymphatic anomalies can contribute to the enlargement of the affected limb. Furthermore, deep lymphatic malformations located in the pelvis and retroperitoneum may lead to compression of intrapelvic organs and disfigurement of the genitalia [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/17\" class=\"abstract_t\">17</a>]. (See <a href=\"topic.htm?path=vascular-lesions-in-the-newborn#H2239122757\" class=\"medical medical_review\">&quot;Vascular lesions in the newborn&quot;, section on 'Lymphatic malformations'</a>.)</p><p class=\"headingAnchor\" id=\"H2422825182\"><span class=\"h2\">Overgrowth</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Limb hypertrophy is often noted at birth and is usually secondary to soft tissue and bony overgrowth, although the presence of venous malformations and lymphedema may be contributing factors (<a href=\"image.htm?imageKey=DERM%2F108290\" class=\"graphic graphic_picture graphicRef108290 \">picture 1C</a>). The affected limb can be both longer in length and larger in circumference compared with the unaffected limb. The natural course of overgrowth is unpredictable but can be progressive [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/14\" class=\"abstract_t\">14</a>].</p><p>Other associated limb anomalies have been reported, including macrodactyly, syndactyly, polydactyly, clinodactyly, camptodactyly, ectrodactyly, and congenital hip dislocation [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/17,18\" class=\"abstract_t\">17,18</a>]. One report suggests that the presence of hand and foot malformations may be a predictor of deep venous anomalies [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/18\" class=\"abstract_t\">18</a>].</p><p class=\"headingAnchor\" id=\"H1878193818\"><span class=\"h2\">Complications</span></p><p class=\"headingAnchor\" id=\"H1656106299\"><span class=\"h3\">Clotting disorders and thromboembolism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Many patients with KTS have ongoing clotting, most commonly a localized intravascular coagulopathy in areas of venous malformation, and an increased risk of superficial thrombophlebitis, and less commonly, of deep venous thrombosis and pulmonary thromboembolism [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/19-21\" class=\"abstract_t\">19-21</a>]. In a cohort of 48 patients with KTS, 23 had a history of superficial venous thrombosis, eight had deep venous thrombosis <span class=\"nowrap\">and/or</span> pulmonary embolism, and two had evidence of chronic pulmonary embolism [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/22\" class=\"abstract_t\">22</a>]. Patients with dilated pelvic veins appear to be at the greatest risk for pulmonary embolism [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/23\" class=\"abstract_t\">23</a>]. Laboratory studies may demonstrate elevated D dimer levels, low fibrinogen, and occasionally thrombocytopenia. (See <a href=\"topic.htm?path=venous-thrombosis-and-thromboembolism-in-children-treatment-prevention-and-outcome\" class=\"medical medical_review\">&quot;Venous thrombosis and thromboembolism in children: Treatment, prevention, and outcome&quot;</a> and <a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-the-nonpregnant-adult-with-suspected-deep-vein-thrombosis-of-the-lower-extremity\" class=\"medical medical_review\">&quot;Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4003071386\"><span class=\"h3\">Bleeding</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Bleeding severity in KTS varies, ranging from minor episodes secondary to vascular &quot;blebs&quot; (ectasias) within capillary stains to severe disseminated intravascular coagulation and major bleeding following invasive procedures. The risk of coagulopathy generally correlates with the extent of venous disease. Intrapelvic and intraabdominal venous malformations and varicosities may result in occult or life-threatening gastrointestinal bleeding and hematuria, most commonly originating from the rectum and bladder, respectively [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/24\" class=\"abstract_t\">24</a>]. It is important to note that the absence of significant venous disease of the extremity does not preclude the presence of pelvic anomalies nor of a coagulopathy [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/6\" class=\"abstract_t\">6</a>].</p><p class=\"headingAnchor\" id=\"H1995292914\"><span class=\"h3\">Limb length discrepancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>KTS may be complicated by variable degrees of limb-length discrepancy. In the lower extremities, length discrepancy may have long-term functional significance, with compensatory tilting and imbalance of the pelvis leading to secondary scoliosis, impaired gait, functional limitations, and pain [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/25\" class=\"abstract_t\">25</a>]. These complications are of greatest concern when the length discrepancy is 2 cm or greater [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/26\" class=\"abstract_t\">26</a>]. Generally, progressive limb overgrowth ceases at the end of adolescence. </p><p class=\"headingAnchor\" id=\"H3555335840\"><span class=\"h3\">Chronic lymphedema/venous insufficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Anomalies of the lymphatic and venous systems predispose KTS patients to chronic lymphedema and chronic venous insufficiency. These may lead to stasis dermatitis and lipodermatosclerosis. Further complications include skin breakdown, recurrent infection, and chronic skin ulcers [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/27\" class=\"abstract_t\">27</a>]. (See <a href=\"topic.htm?path=stasis-dermatitis\" class=\"medical medical_review\">&quot;Stasis dermatitis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3997896703\"><span class=\"h3\">Cellulitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with KTS are susceptible to recurrent bouts of cellulitis. In one study of 252 patients with KTS, 13 percent suffered from cellulitis [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/6\" class=\"abstract_t\">6</a>]. It is uncertain whether cellulitis is in all cases due to bacterial infection. In a subset of patients, it may represent an inflammatory reaction to venous stasis, chronic lymphedema, or thrombosis. Nonetheless, it is prudent to have a high clinical suspicion for infection if new-onset erythema, pain, swelling, and warmth are present, or if fever is associated with increased pain or heaviness of the affected area, even in the absence of overt signs of cellulitis. (See <a href=\"topic.htm?path=cellulitis-and-skin-abscess-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Cellulitis and skin abscess: Clinical manifestations and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H849909441\"><span class=\"h3\">Pain</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pain can be a common and often debilitating aspect of KTS, with studies documenting a prevalence of 37 to 88 percent [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/6,28\" class=\"abstract_t\">6,28</a>]. The etiology of pain is multifactorial and likely includes chronic venous insufficiency, cellulitis, superficial thrombophlebitis, deep vein thrombosis, &quot;growing pains,&quot; intraosseous involvement, arthritis and contractures, in part attributable to intraarticular involvement and hemarthrosis, and neuropathic pain [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/27\" class=\"abstract_t\">27</a>]. </p><p class=\"headingAnchor\" id=\"H826863360\"><span class=\"h1\">PATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A skin biopsy is not routinely performed in patients with Klippel-Trenaunay syndrome (KTS). If performed, it shows the histopathologic features of the various types of vascular malformation, lipomatous overgrowth, and, in older lesions, secondary changes from clotting, infection, and other complications.</p><p>Capillary malformations demonstrate ectatic capillary vessels in the superficial dermis, which, in later stages, become more prominent with fibrous wall thickening and possible extension into the deep dermis [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/29\" class=\"abstract_t\">29</a>]. Venous malformations are characterized by irregular vessels containing erythrocytes, with a single layer of endothelial cells, absent internal elastic membrane, and often scant smooth muscle in the vessel wall [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/29\" class=\"abstract_t\">29</a>]. </p><p>Thrombi or phleboliths may be evident. The histology of an excised persistent lateral marginal vein shows features similar to that of varicose veins in the general population [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/30\" class=\"abstract_t\">30</a>]. </p><p>Lymphatic malformations appear as numerous irregular dilated spaces in the dermis and subcutaneous tissue lined by a single layer of endothelial cells and variable smooth muscle with surrounding loose or fibrotic stroma and lymphocytic aggregates. In contrast to venous malformations, those of lymphatic origin contain a pink proteinaceous fluid with occasional erythrocytes, and their endothelial lining stains with the monoclonal antibody D2-40, a marker of lymphatic endothelium [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/29\" class=\"abstract_t\">29</a>].</p><p class=\"headingAnchor\" id=\"H2952888392\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of Klippel-Trenaunay syndrome (KTS) is primarily based upon the presence of the key clinical features discussed above, which include capillary malformation, venous malformation, and limb overgrowth, with or without lymphatic malformation (see <a href=\"#H3383733452\" class=\"local\">'Clinical manifestations'</a> above). That said, radiologic evaluation and laboratory testing may be critical in securing the diagnosis.</p><p class=\"headingAnchor\" id=\"H1885598182\"><span class=\"h2\">Imaging studies</span></p><p class=\"headingAnchor\" id=\"H277152775\"><span class=\"h3\">Ultrasonography</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><span class=\"nowrap\">Doppler/duplex</span> ultrasound is helpful in identifying anomalies of the superficial and deep venous systems. It provides confirmation of low flow, compressible vascular channels, valvular incompetence, and anatomical abnormalities such as atresia or aneurysms [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/17\" class=\"abstract_t\">17</a>]. It is also the test of choice for the detection of acute venous thrombosis and phleboliths. On ultrasonography, venous malformations appear as phlebectatic or spongiform hypoechoic masses, while lymphatic malformations are mostly cystic [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/23\" class=\"abstract_t\">23</a>]. Ultrasonography is inexpensive and can be performed without sedation in infants and young children. Disadvantages include its high interoperator variability and poor soft-tissue contrast [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/23\" class=\"abstract_t\">23</a>]. (See <a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-the-nonpregnant-adult-with-suspected-deep-vein-thrombosis-of-the-lower-extremity#H1036971809\" class=\"medical medical_review\">&quot;Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity&quot;, section on 'Diagnostic ultrasonography suspected first DVT'</a>.)</p><p class=\"headingAnchor\" id=\"H46352013\"><span class=\"h3\">Magnetic resonance imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Magnetic resonance imaging (MRI), with and without gadolinium contrast, is the imaging study of choice to define the nature and extent of vascular anomalies in patients with KTS (<a href=\"image.htm?imageKey=DERM%2F108942\" class=\"graphic graphic_diagnosticimage graphicRef108942 \">image 1</a>). MRI provides the highest diagnostic accuracy in the evaluation of the underlying venous and lymphatic abnormalities, as well as soft tissue and bony overgrowth. Venous malformations show uniform enhancement, whereas lymphatic malformations demonstrate rim or septal enhancement of cyst walls [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/23\" class=\"abstract_t\">23</a>]. Fluid-fluid levels and high T2 signal intensity are characteristic of lymphatic malformations [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/31\" class=\"abstract_t\">31</a>]. The presence of phleboliths as signal voids is characteristic of venous malformations [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/31\" class=\"abstract_t\">31</a>]. </p><p>In patients with severe disease involving the lower extremity and perineum, magnetic resonance venography (MRV) should be considered. The finding of large pelvic veins indicates an increased risk of pulmonary embolism [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/23\" class=\"abstract_t\">23</a>]. Though MRI is the imaging study of choice, testing can be costly and may require sedation for younger patients. (See <a href=\"topic.htm?path=anesthesia-for-magnetic-resonance-imaging-and-computed-tomography-procedures\" class=\"medical medical_review\">&quot;Anesthesia for magnetic resonance imaging and computed tomography procedures&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3378638044\"><span class=\"h3\">Conventional venography</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Contrast venography is useful to assess the anatomy and patency of the superficial and deep venous systems before and after endovascular or intralesional treatment of varicosities and venous malformations [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/14,32\" class=\"abstract_t\">14,32</a>]. (See <a href=\"#H3744279357\" class=\"local\">'Surgical therapies'</a> below.)</p><p class=\"headingAnchor\" id=\"H2222240455\"><span class=\"h3\">Plain radiograph</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Scanogram, orthoroentgenogram, and teleroentgenogram are standard radiographic techniques used in conjunction with leg length measurements for the evaluation of leg length discrepancy, bony hypertrophy, and additional osseous anomalies, which may include syndactyly, polydactyly, and congenital hip dislocation [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/32,33\" class=\"abstract_t\">32,33</a>]. Serial plain films may also be obtained to monitor patients with secondary scoliosis. </p><p class=\"headingAnchor\" id=\"H3199488687\"><span class=\"h2\">Laboratory studies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Baseline complete blood count (CBC), D-dimer, fibrinogen, prothrombin time (PT), and partial thromboplastin time (PTT) should be performed in all patients with suspected KTS. Elevated D-dimer with or without low fibrinogen suggests chronic localized intravascular coagulopathy. (See <a href=\"#H1656106299\" class=\"local\">'Clotting disorders and thromboembolism'</a> above.)</p><p>Repeat coagulation studies should be performed periodically, and especially prior to any invasive procedures or during pregnancy, as KTS patients have an increased risk of deep vein thrombosis and pulmonary thromboembolism in these settings [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/23,34\" class=\"abstract_t\">23,34</a>]. Testing may also be prompted by the finding of phleboliths on clinical examination or imaging. </p><p class=\"headingAnchor\" id=\"H2180466713\"><span class=\"h2\">Biopsy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A biopsy for histopathologic confirmation is typically not necessary to confirm the diagnosis of KTS. However, obtaining a punch or incisional biopsy of the involved tissue can be valuable for the purposes of molecular and genetic testing. In particular, the use of next-generation sequencing, droplet digital polymerase chain reaction, and single molecule molecular inversion probes has helped to capture somatic <em>PIK3CA</em> mutations in affected individuals [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/4,35\" class=\"abstract_t\">4,35</a>]. A more inclusive approach using a panel including several genes causing overgrowth has been successful in identifying somatic mutations [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/35\" class=\"abstract_t\">35</a>]. This analysis can be performed on paraffin-embedded tissue. </p><p class=\"headingAnchor\" id=\"H620490315\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of Klippel-Trenaunay syndrome (KTS) from other capillary malformation-overgrowth syndromes is summarized in the table (<a href=\"image.htm?imageKey=DERM%2F108302\" class=\"graphic graphic_table graphicRef108302 \">table 1</a>) and discussed below. It includes isolated capillary malformation, diffuse capillary malformation with overgrowth (DCMO), Parkes Weber syndrome, and other overgrowth syndromes.</p><p class=\"headingAnchor\" id=\"H3937083077\"><span class=\"h2\">Capillary malformation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Isolated capillary malformations (port-wine stains) of the limb, in the absence of varicosities, venous or lymphatic malformations, and overgrowth, carry a much better prognosis than KTS with few complications (<a href=\"image.htm?imageKey=DERM%2F108302\" class=\"graphic graphic_table graphicRef108302 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/16\" class=\"abstract_t\">16</a>]. In uncertain cases or in cases in which lesions are symptomatic (eg, painful, warm to the touch), ultrasonography or magnetic resonance imaging (MRI) should be performed to exclude KTS or Parkes Weber syndrome.</p><p>In patients with diffuse capillary malformation, monitoring of head circumference and neurologic development and, if appropriate, serial neuroimaging may be indicated to exclude macrocephaly-capillary malformation (M-CM) [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/2\" class=\"abstract_t\">2</a>]. (See <a href=\"topic.htm?path=capillary-malformations-port-wine-stains-and-associated-syndromes\" class=\"medical medical_review\">&quot;Capillary malformations (port wine stains) and associated syndromes&quot;</a> and <a href=\"#H3124645245\" class=\"local\">'Macrocephaly-capillary malformation'</a> below.)</p><p class=\"headingAnchor\" id=\"H3248521004\"><span class=\"h2\">Diffuse capillary malformation with overgrowth</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Many patients previously diagnosed as having KTS have findings consistent with diffuse capillary malformation with overgrowth (DCMO) [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/2\" class=\"abstract_t\">2</a>]. Some cases of DCMO have been associated with somatic mutations in the <em>GNA11</em> gene [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/36\" class=\"abstract_t\">36</a>]. Affected individuals typically have extensive capillary malformations, often with a reticulated pattern in some areas, in the setting of proportionate, nonprogressive overgrowth (<a href=\"image.htm?imageKey=DERM%2F108305\" class=\"graphic graphic_picture graphicRef108305 \">picture 2</a>). The capillary malformations are often more widespread but fainter in color than those seen in KTS and lack the characteristic geographic, sharply demarcated borders (<a href=\"image.htm?imageKey=DERM%2F108302\" class=\"graphic graphic_table graphicRef108302 \">table 1</a>). </p><p>Approximately one-third of patients with DCMO have prominent varicosities, thus fulfilling the classic KTS triad of capillary stain, overgrowth, and venous malformations. However, the venous malformations in DCMO do not include the persistent embryonic veins and deep venous anomalies typically seen in KTS. Most notably, DCMO lacks any evidence of lymphatic malformations. These differences have a prognostic significance, since patients with DCMO are at low risk for cellulitis, coagulopathy, pulmonary embolism, and progressive overgrowth [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/2,37\" class=\"abstract_t\">2,37</a>]. It is important to monitor patients with a provisional diagnosis of DCMO, particularly infants and young children, to ensure that this, rather than KTS, is the correct diagnosis.</p><p class=\"headingAnchor\" id=\"H3310890272\"><span class=\"h2\">Parkes Weber syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Parkes Weber syndrome is defined by the combination of capillary malformation, fast-flow arteriovenous fistulae, and limb overgrowth, preferentially involving the lower extremity [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/1\" class=\"abstract_t\">1</a>]. Parkes Weber syndrome has been associated with mutations in the <em>RASA1</em> gene, particularly when smaller capillary stains are present on other parts of the body [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/38\" class=\"abstract_t\">38</a>]. Unlike KTS, structural venous anomalies and lymphatic malformations are frequently absent, though enlarged veins due to venous hypertension may be present (<a href=\"image.htm?imageKey=DERM%2F108302\" class=\"graphic graphic_table graphicRef108302 \">table 1</a>). </p><p>Parkes Weber syndrome and KTS can be difficult to distinguish in younger patients. Clues to the diagnosis of Parkes Weber syndrome include brighter pink stains with rapid capillary refill, unusual skin warmth, lack of lymphatic disease, and excessive pain out of proportion for physical findings. Doppler ultrasound studies may demonstrate high flow within the vascular stains or adjacent soft tissue.</p><p class=\"headingAnchor\" id=\"H274756352\"><span class=\"h2\">Servelle-Martorell syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Servelle-Martorell syndrome is a rare congenital angiodysplastic disease presenting with capillary and venous malformations, but with decreased<em> </em>rather than increased limb girth due to bone undergrowth [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/39\" class=\"abstract_t\">39</a>]. It can be confused with KTS, but the progressive limb hypotrophy rather than overgrowth helps in differentiating the two conditions.</p><p class=\"headingAnchor\" id=\"H3124645245\"><span class=\"h2\">Macrocephaly-capillary malformation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Capillary malformation, asymmetric overgrowth, and digital anomalies <span class=\"nowrap\">(syndactyly/polydactyly)</span> represent overlapping features in both macrocephaly-capillary malformation (M-CM) and KTS (<a href=\"image.htm?imageKey=DERM%2F108302\" class=\"graphic graphic_table graphicRef108302 \">table 1</a>), although the capillary malformation in M-CM tends to be diffuse and reticulate. The presence of midline facial vascular stains, <span class=\"nowrap\">skin/joint</span> laxity, increased head circumference, and severe neurologic disease favor the diagnosis of M-CM. Additional neurologic findings in M-CM include developmental delay, seizures, hypotonia, frontal bossing, hydrocephalus, ventriculomegaly, polymicrogyria, cerebral <span class=\"nowrap\">and/or</span> cerebellar asymmetry, and cerebellar tonsillar herniation [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/40\" class=\"abstract_t\">40</a>]. Like KTS, M-CM appears to fall under the umbrella of <em>PIK3CA</em>-related overgrowth spectrum (PROS) [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/11\" class=\"abstract_t\">11</a>]. </p><p class=\"headingAnchor\" id=\"H516434826\"><span class=\"h2\">CLOVES syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and skeletal anomalies (CLOVES) syndrome are sometimes initially diagnosed as having KTS, since the early clinical findings are virtually identical (<a href=\"image.htm?imageKey=DERM%2F108302\" class=\"graphic graphic_table graphicRef108302 \">table 1</a>), while the lipomatous overgrowth and epidermal nevi tend to appear later. The substantial clinical overlap between KTS and CLOVES is likely explained by the identification of similar somatic <em>PIK3CA</em> mutations in both conditions [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/13\" class=\"abstract_t\">13</a>]. </p><p>Clues to the diagnosis of CLOVES include facial asymmetry and macrodactyly with &quot;sandal gap&quot; toe deformity [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/41\" class=\"abstract_t\">41</a>]. High-flow spinal and paraspinal arteriovenous malformations have also been reported in CLOVES syndrome [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/42\" class=\"abstract_t\">42</a>]. (See <a href=\"topic.htm?path=vascular-lesions-in-the-newborn#H289635786\" class=\"medical medical_review\">&quot;Vascular lesions in the newborn&quot;, section on 'CLOVES syndrome'</a>.)</p><p class=\"headingAnchor\" id=\"H3183845736\"><span class=\"h2\">Proteus syndrome/PTEN hamartoma tumor syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Proteus syndrome is caused by activating mutations in the <em>AKT1</em> gene [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/43\" class=\"abstract_t\">43</a>], resulting in asymmetric, disproportionate, and progressive overgrowth of soft tissue and bone, and extensive cutaneous and visceral mixed vascular malformations. Distinct clinical characteristics of Proteus syndrome that set it apart from KTS include cerebriform connective tissue nevi of the plantar feet (<a href=\"image.htm?imageKey=ONC%2F73826\" class=\"graphic graphic_picture graphicRef73826 \">picture 3</a>), epidermal nevi, lipomas, caf&eacute; au lait macules, macrocephaly, learning difficulties, pulmonary cysts, and ovarian cystadenomas [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/44\" class=\"abstract_t\">44</a>]. </p><p>PTEN hamartoma tumor syndrome also encompasses the Bannayan-Riley-Ruvalcaba syndrome (BRRS), which shares overlapping features with Proteus syndrome, including macrocephaly, developmental delay, lipomas, and vascular malformations. Unique to BRRS are genital lentigines, gastrointestinal polyposis, and pseudopapilledema [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/45\" class=\"abstract_t\">45</a>]. </p><p class=\"headingAnchor\" id=\"H3052860088\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The management of patients with Klippel-Trenaunay syndrome (KTS) requires a multidisciplinary approach, ideally in a multidisciplinary vascular anomalies center. Consultations with pediatric dermatology, interventional radiology, plastic surgery, orthopedic surgery, vascular surgery, hematology, urology, gastroenterology, physical and occupational therapy, and pain management may be warranted. The approach should be individualized, based upon the extent of disease and complications. For many patients, treatment is mainly supportive, centering on the prevention and management of complications. Medical, interventional radiologic, or surgical interventions may be necessary if there are significant symptoms or functional impairment.</p><p class=\"headingAnchor\" id=\"H3525030370\"><span class=\"h2\">Supportive treatment and surveillance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with KTS are at risk for severe and chronic edema of the affected limb due to venous and lymphatic insufficiency. Conservative management includes compression garments, lymphatic massage, physical therapy, and physical activity [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/46\" class=\"abstract_t\">46</a>]. (See <a href=\"topic.htm?path=clinical-staging-and-conservative-management-of-peripheral-lymphedema\" class=\"medical medical_review\">&quot;Clinical staging and conservative management of peripheral lymphedema&quot;</a>.)</p><p>Compression garments should extend from above the affected area to cover the distal digits. Reducing edema may decrease the risk of recurrent cellulitis and chronic wounds as well as improve mobility and comfort. There is no evidence, however, that compression reduces soft tissue hypertrophy. Young children tend not to tolerate compression garments and quickly outgrow them, a reality which should be considered in deciding at what age to recommend compression. </p><p>Patients with isolated hemihypertrophy or overgrowth syndromes (eg, Beckwith-Wiedemann syndrome, Sotos syndrome, Perlman syndrome) have an increased risk of embryonal tumors such as Wilms tumor and hepatoblastoma [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/47\" class=\"abstract_t\">47</a>]. Tumor screening with serial renal ultrasounds and serum alpha fetoprotein measurements is therefore recommended for these patients until age eight. (See <a href=\"topic.htm?path=beckwith-wiedemann-syndrome\" class=\"medical medical_review\">&quot;Beckwith-Wiedemann syndrome&quot;</a>.) </p><p>Although the embryonal tumor risk in&nbsp;<em>PIK3CA</em>-related segmental overgrowth&nbsp;syndromes such as macrocephaly-capillary malformation (M-CM) and congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and skeletal anomalies (CLOVES) syndrome is still undetermined, some experts suggest that these patients also be screened for Wilms tumor [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/48\" class=\"abstract_t\">48</a>]. However, for patients with KTS without the additional features of CLOVES syndrome, screening for Wilms tumor is not generally recommended since data do not suggest an increased risk [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/49\" class=\"abstract_t\">49</a>]. Patients with diffuse capillary malformation with overgrowth (DCMO) are likely not at increased risk for Wilms tumor as well, unless there is associated hemihypertrophy [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/50\" class=\"abstract_t\">50</a>].</p><p class=\"headingAnchor\" id=\"H3998823637\"><span class=\"h2\">Management of leg length discrepancy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All patients with KTS should be followed closely for leg length discrepancy using regular measurements of distance between the anterior superior iliac spine and medial malleolus, especially during periods of rapid somatic growth [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/33\" class=\"abstract_t\">33</a>]. Generally, a less than 2 cm difference is considered inconsequential and can be managed with shoe lifts. When discrepancies are greater than 2 cm, comanagement with orthopedics is recommended. Halting growth of the longer leg to reduce such a discrepancy is achieved through an epiphysiodesis (obliteration of the growth plate) [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/25\" class=\"abstract_t\">25</a>]. The timing of this procedure is crucial.</p><p class=\"headingAnchor\" id=\"H3004682947\"><span class=\"h2\">Medical treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The medical management for KTS involves the treatment of coagulation disorders, treatment and prevention of infection, pain management, and, if possible, pathogenesis-directed therapy.</p><p class=\"headingAnchor\" id=\"H3052945077\"><span class=\"h3\">Chronic coagulopathy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chronic coagulopathy, as evidenced by elevated D-dimer, low fibrinogen, and presence of phleboliths or signs of superficial thrombophlebitis on clinical examination and imaging studies, is common in KTS patients with extensive venous malformations. Low-dose <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> appears to be beneficial in patients with venous malformations, with improvement of pain and swelling [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/51\" class=\"abstract_t\">51</a>]. Although there are no specific data on its use in KTS, low-dose aspirin is a reasonable first-line treatment for patients with laboratory or clinical evidence of chronic coagulopathy. </p><p>Patients with established thromboses or thromboembolism require long-term treatment with oral or parenteral anticoagulants. Coordination of care with hematologists is strongly recommended. (See <a href=\"topic.htm?path=direct-oral-anticoagulants-and-parenteral-direct-thrombin-inhibitors-dosing-and-adverse-effects\" class=\"medical medical_review\">&quot;Direct oral anticoagulants and parenteral direct thrombin inhibitors: Dosing and adverse effects&quot;</a> and <a href=\"topic.htm?path=venous-thromboembolism-anticoagulation-after-initial-management\" class=\"medical medical_review\">&quot;Venous thromboembolism: Anticoagulation after initial management&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1361017158\"><span class=\"h3\">Infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with KTS, especially those who have associated lymphatic anomalies, are predisposed to recurrent cellulitis and lymphangitis. In severe cases, skin infections can progress to bacteremia and sepsis [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/52\" class=\"abstract_t\">52</a>]. If possible, cultures should be obtained to help in directing therapy, although they can often be negative despite signs and symptoms of infection. </p><p>Patients with suspected cellulitis should receive early empiric treatment with antibiotics effective against beta-hemolytic streptococci and methicillin-sensitive <em>S. aureus</em>, such as penicillin, <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a>, or first-generation cephalosporins, as well as meticulous wound care. Additional empiric coverage for methicillin-resistant <em>S. aureus</em> is warranted in patients who do not respond to initial therapy. (See <a href=\"topic.htm?path=cellulitis-and-skin-abscess-in-adults-treatment\" class=\"medical medical_review\">&quot;Cellulitis and skin abscess in adults: Treatment&quot;</a>.)</p><p>Although there are no data to support the use of chronic or prophylactic antibiotic therapy in patients with KTS, suppressive antibiotic therapy may be indicated in those with recurrent skin infections. (See <a href=\"topic.htm?path=cellulitis-and-skin-abscess-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Cellulitis and skin abscess: Clinical manifestations and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H113413074\"><span class=\"h3\">Pain control</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pain is a significant source of morbidity in patients with KTS. As previously noted, the etiology of pain in KTS is often multifactorial and treatment can be extremely challenging. Addressing the underlying cause of pain is critical and involves targeted treatment of infection, superficial or deep vein thrombosis, contractures, and neuropathic pain [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/27\" class=\"abstract_t\">27</a>]. Nonsteroidal antiinflammatory drugs (NSAIDs) and opiates are frequently prescribed, but may only be provide only temporary relief. Ultimately, reducing the burden of vascular malformation, including <span class=\"nowrap\">intraosseous/articular</span> disease, through surgical and endovascular interventions may be required as a means of pain management.</p><p class=\"headingAnchor\" id=\"H2831547210\"><span class=\"h3\">mTOR inhibitors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The mammalian target of rapamycin (mTOR) inhibitor <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a> has emerged as a potential therapeutic option for complex venous-lymphatic malformations, including in the setting of KTS [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/53-58\" class=\"abstract_t\">53-58</a>]. Its primary mechanism of action is the inhibition of mTOR, which acts downstream of the <span class=\"nowrap\">PI3K/AKT</span> pathway to promote cell proliferation and angiogenesis. Promising results have been reported in preliminary studies. &#160;</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the first 2011 report, one patient with kaposiform hemangioendothelioma, one with capillary-lymphatic-venous malformation, and four with microcystic lymphatic malformations were treated with <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a>, with dramatic improvement in clinical status and reduction in size of the vascular anomalies [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/53\" class=\"abstract_t\">53</a>]. Initial dosing was 0.8 <span class=\"nowrap\">mg/m<sup>2</sup></span> per dose given twice daily, with a goal trough of 10 to 15 <span class=\"nowrap\">ng/mL</span>. Adverse effects of sirolimus include mucositis, headache, hyperlipidemia, transaminitis, myelosuppression, and infection [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/53,55\" class=\"abstract_t\">53,55</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One study presented the first mouse model for human venous malformations and demonstrated effective growth suppression with rapamycin (<a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a>) [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/59\" class=\"abstract_t\">59</a>]. The authors also conducted a pilot clinical study in five patients with venous malformations and one with KTS. Treatment with sirolimus resulted in improvement in pain, quality of life, functional impairment, bleeding, coagulation parameters, and lesion size.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The first prospective trial on the safety and efficacy of <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a> for complex vascular anomalies was published in February 2016 [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/60\" class=\"abstract_t\">60</a>]. Sixty-one patients, including 13 with mixed capillary-venous-lymphatic malformations, were treated with 12 consecutive 28-day courses of sirolimus. Forty-five of 53 patients (85 percent) who completed 12 courses of treatment had a partial response to sirolimus, as assessed by imaging studies, and reported improvement in quality of life and function. The most common adverse effect was bone marrow toxicity in 27 percent of patients. &#160;</p><p/><p>Consultation with hematology is recommended for initiation of <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a>. The optimal duration of treatment is not yet known. Further studies are necessary to evaluate the efficacy and safety of sirolimus for the treatment of KTS and to establish treatment guidelines and protocols.</p><p class=\"headingAnchor\" id=\"H3744279357\"><span class=\"h2\">Surgical therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Superficial vascular stains and lymphatic blebs if recurrently bleeding, leaking, or crusting may be treated with laser therapy. The pulsed dye laser is effective in lightening capillary malformations, whereas ablative CO<sub>2</sub> lasers are often more useful in controlling leakage and bleeding from lymphatic vesicles. (See <a href=\"topic.htm?path=laser-and-light-therapy-for-cutaneous-vascular-lesions#H10061356\" class=\"medical medical_review\">&quot;Laser and light therapy for cutaneous vascular lesions&quot;, section on 'Port wine stains'</a>.)</p><p>When conservative measures, such as the use of compression garments, are inadequate, endovascular ablation with laser, radiofrequency, or sclerotherapy have been used for the treatment of venous and lymphatic disease with good results [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/46,61\" class=\"abstract_t\">46,61</a>]. Early ablation of embryonal veins in young children has been proposed, as minimally invasive techniques have limitations as veins enlarge over time [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/17\" class=\"abstract_t\">17</a>]. Ablation of anomalous veins, however, does not prevent limb overgrowth [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/62\" class=\"abstract_t\">62</a>]. Macrocystic components of lymphatic malformations respond particularly well to sclerotherapy [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/63\" class=\"abstract_t\">63</a>]. Multiple treatments over years are the norm. </p><p>Symptomatic varicosities have also been successfully treated with vein stripping, high ligation, or ambulatory phlebectomy [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/64\" class=\"abstract_t\">64</a>]. Prior to the performance of these procedures, it is important to assess the patency of the deep venous system with magnetic resonance imaging <span class=\"nowrap\">and/or</span> venography. (See <a href=\"topic.htm?path=open-surgical-techniques-for-lower-extremity-vein-ablation\" class=\"medical medical_review\">&quot;Open surgical techniques for lower extremity vein ablation&quot;</a> and <a href=\"topic.htm?path=endovenous-laser-ablation-for-the-treatment-of-lower-extremity-chronic-venous-disease\" class=\"medical medical_review\">&quot;Endovenous laser ablation for the treatment of lower extremity chronic venous disease&quot;</a> and <a href=\"topic.htm?path=liquid-foam-and-glue-sclerotherapy-techniques-for-the-treatment-of-lower-extremity-veins\" class=\"medical medical_review\">&quot;Liquid, foam, and glue sclerotherapy techniques for the treatment of lower extremity veins&quot;</a>.)</p><p>Surgical resection is most desirable to treat localized or superficial components, as a means of improving function and mobility, reducing the risk of infection, and managing chronic bleeding, lymph leakage, and ulceration. Complete surgical removal of extensive vascular malformations is typically not feasible, especially when they extend deep into muscle and bone. Persistent and life-threatening gastrointestinal or genitourinary bleeds or obstruction may prompt radical resection of pelvic malformations [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/65,66\" class=\"abstract_t\">65,66</a>]. &#160;</p><p>Debulking of overgrown soft tissue and amputation may be considered in selected patients with severe progressive overgrowth and inability to ambulate. Ray resection and foot amputation can aid in improving gait. In cases of severe flexion contracture, amputation at the knee may be indicated [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/17\" class=\"abstract_t\">17</a>]. Before pursuing these procedures, patients must be informed of the risks and potential complications, including but not limited to bleeding, worsening edema, seroma, chronic lymphatic leakage, pain, infection, and poor wound healing. If surgical debulking is planned, it may be prudent to start more distally to avoid further worsening of the distal lymphatic or venous drainage.</p><p class=\"headingAnchor\" id=\"H2755843852\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The prognosis of Klippel-Trenaunay syndrome (KTS) is variable and depends upon the extent of disease and presence of complications. Life-threatening massive pulmonary embolism has been reported, although the exact incidence is not known. In one series of 75 KTS patients, 39 percent experienced thromboembolic complications, including superficial thrombosis, and 8 percent had either a deep vein thrombosis or pulmonary thromboembolism [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/21\" class=\"abstract_t\">21</a>]. Some patients may develop chronic thromboembolic pulmonary hypertension [<a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/22\" class=\"abstract_t\">22</a>].</p><p class=\"headingAnchor\" id=\"H3228166582\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Klippel-Trenaunay syndrome (KTS) is a rare congenital disorder characterized by the presence of capillary malformation, venous malformation or varicosities, and limb overgrowth, with or without lymphatic anomalies (<a href=\"image.htm?imageKey=DERM%2F108288%7EDERM%2F108290\" class=\"graphic graphic_picture graphicRef108288 graphicRef108290 \">picture 1A, 1C</a>). KTS is considered part of the <em>PIK3CA</em>-related overgrowth spectrum (PROS). (See <a href=\"#H738068296\" class=\"local\">'Introduction'</a> above and <a href=\"#H2839404764\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The cutaneous vascular stains (port-wine stains) of KTS are noted at birth and most commonly involve the lower extremity. They are classified as geographic or <span class=\"nowrap\">blotchy/segmental</span>. Geographic stains are usually dark-red or purple in color and have a sharply demarcated, irregular shape resembling that of a country or continent (<a href=\"image.htm?imageKey=DERM%2F108288%7EDERM%2F108289\" class=\"graphic graphic_picture graphicRef108288 graphicRef108289 \">picture 1A-B</a>). (See <a href=\"#H3037764232\" class=\"local\">'Capillary malformation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The persistence of avalvular embryonal veins (lateral vein of the thigh and sciatic vein) is a venous malformation characteristic of KTS; it results in dilated tortuous varicosities, most often located over the anterolateral thigh and leg (<a href=\"image.htm?imageKey=DERM%2F108289\" class=\"graphic graphic_picture graphicRef108289 \">picture 1B</a>). Structural abnormalities of the deep venous system can also occur. (See <a href=\"#H3542307160\" class=\"local\">'Venous malformation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Limb hypertrophy is often noted at birth and is usually secondary to soft tissue and bony overgrowth, although the presence of venous malformations and lymphedema may be contributing factors (<a href=\"image.htm?imageKey=DERM%2F108290\" class=\"graphic graphic_picture graphicRef108290 \">picture 1C</a>). (See <a href=\"#H2422825182\" class=\"local\">'Overgrowth'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complications of KTS include clotting disorder and chronic thromboembolism, bleeding, limb length discrepancy, lymphedema, soft-tissue infection, and pain. (See <a href=\"#H1878193818\" class=\"local\">'Complications'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of KTS is, in most cases, made clinically. Magnetic resonance imaging, with and without contrast, is the best way to confirm and assess the extent of underlying venous and lymphatic disease as well as soft tissue and bony overgrowth (<a href=\"image.htm?imageKey=DERM%2F108942\" class=\"graphic graphic_diagnosticimage graphicRef108942 \">image 1</a>). (See <a href=\"#H2952888392\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The management of patients with KTS requires a multidisciplinary approach, ideally in a multidisciplinary vascular anomalies center. Treatment should be individualized and may include supportive care; medical management of coagulopathy, infection, and pain; orthopedic interventions for limb length discrepancy; and surgical interventions to reduce tissue overgrowth and improve function. <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">Sirolimus</a> is emerging as an important targeted treatment for the complex venous-lymphatic malformations in KTS. (See <a href=\"#H3052860088\" class=\"local\">'Management'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The prognosis of KTS is variable and depends upon the extent of disease and presence of complications. Some patients may develop pulmonary embolism and chronic thromboembolic pulmonary hypertension. (See <a href=\"#H2755843852\" class=\"local\">'Prognosis'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/1\" class=\"nounderline abstract_t\">Wassef M, Blei F, Adams D, et al. Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular Anomalies. Pediatrics 2015; 136:e203.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/2\" class=\"nounderline abstract_t\">Lee MS, Liang MG, Mulliken JB. Diffuse capillary malformation with overgrowth: a clinical subtype of vascular anomalies with hypertrophy. J Am Acad Dermatol 2013; 69:589.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/3\" class=\"nounderline abstract_t\">Vahidnezhad H, Youssefian L, Uitto J. Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS). Exp Dermatol 2016; 25:17.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/4\" class=\"nounderline abstract_t\">Luks VL, Kamitaki N, Vivero MP, et al. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr 2015; 166:1048.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/5\" class=\"nounderline abstract_t\">McCuaig CC. Update on classification and diagnosis of vascular malformations. Curr Opin Pediatr 2017; 29:448.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/6\" class=\"nounderline abstract_t\">Jacob AG, Driscoll DJ, Shaughnessy WJ, et al. Klippel-Tr&eacute;naunay syndrome: spectrum and management. Mayo Clin Proc 1998; 73:28.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/7\" class=\"nounderline abstract_t\">Craven N, Wright AL. Familial Klippel-Trenaunay syndrome: a case report. Clin Exp Dermatol 1995; 20:76.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/8\" class=\"nounderline abstract_t\">Steijlen PM, van Steensel MA. Paradominant inheritance, a hypothesis explaining occasional familial occurrence of sporadic syndromes. Am J Med Genet 1999; 85:359.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/9\" class=\"nounderline abstract_t\">Tian XL, Kadaba R, You SA, et al. Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome. Nature 2004; 427:640.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/10\" class=\"nounderline abstract_t\">Timur AA, Sadgephour A, Graf M, et al. Identification and molecular characterization of a de novo supernumerary ring chromosome 18 in a patient with Klippel-Trenaunay syndrome. Ann Hum Genet 2004; 68:353.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/11\" class=\"nounderline abstract_t\">Alomari AI, Spencer SA, Arnold RW, et al. Fibro-adipose vascular anomaly: clinical-radiologic-pathologic features of a newly delineated disorder of the extremity. J Pediatr Orthop 2014; 34:109.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/12\" class=\"nounderline abstract_t\">Yeung KS, Ip JJ, Chow CP, et al. Somatic PIK3CA mutations in seven patients with PIK3CA-related overgrowth spectrum. Am J Med Genet A 2017; 173:978.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/13\" class=\"nounderline abstract_t\">Keppler-Noreuil KM, Rios JJ, Parker VE, et al. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A 2015; 167A:287.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/14\" class=\"nounderline abstract_t\">Garzon MC, Huang JT, Enjolras O, Frieden IJ. Vascular malformations. Part II: associated syndromes. J Am Acad Dermatol 2007; 56:541.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/15\" class=\"nounderline abstract_t\">Maari C, Frieden IJ. Klippel-Tr&eacute;naunay syndrome: the importance of &quot;geographic stains&quot; in identifying lymphatic disease and risk of complications. J Am Acad Dermatol 2004; 51:391.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/16\" class=\"nounderline abstract_t\">Redondo P, Aguado L, Mart&iacute;nez-Cuesta A. Diagnosis and management of extensive vascular malformations of the lower limb: part I. Clinical diagnosis. J Am Acad Dermatol 2011; 65:893.</a></li><li class=\"breakAll\">Mulliken JB, Young AE. Vascular Birthmarks: Hemangiomas and Malformations, Saunders, Philadelphia 1988.</li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/18\" class=\"nounderline abstract_t\">Redondo P, Bastarrika G, Aguado L, et al. Foot or hand malformations related to deep venous system anomalies of the lower limb in Klippel-Tr&eacute;naunay syndrome. J Am Acad Dermatol 2009; 61:621.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/19\" class=\"nounderline abstract_t\">Mazoyer E, Enjolras O, Bisdorff A, et al. Coagulation disorders in patients with venous malformation of the limbs and trunk: a case series of 118 patients. Arch Dermatol 2008; 144:861.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/20\" class=\"nounderline abstract_t\">Huiras EE, Barnes CJ, Eichenfield LF, et al. Pulmonary thromboembolism associated with Klippel-Trenaunay syndrome. Pediatrics 2005; 116:e596.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/21\" class=\"nounderline abstract_t\">Oduber CE, van Beers EJ, Bresser P, et al. Venous thromboembolism and prothrombotic parameters in Klippel-Trenaunay syndrome. Neth J Med 2013; 71:246.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/22\" class=\"nounderline abstract_t\">Douma RA, Oduber CE, Gerdes VE, et al. Chronic pulmonary embolism in Klippel-Trenaunay syndrome. J Am Acad Dermatol 2012; 66:71.</a></li><li class=\"breakAll\">Severe Skin Diseases in Children: Beyond Topical Therapy, Wynnis T (Ed), Springer, Berlin 2014.</li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/24\" class=\"nounderline abstract_t\">Cha SH, Romeo MA, Neutze JA. Visceral manifestations of Klippel-Tr&eacute;naunay syndrome. Radiographics 2005; 25:1694.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/25\" class=\"nounderline abstract_t\">Enjolras O, Chapot R, Merland JJ. Vascular anomalies and the growth of limbs: a review. J Pediatr Orthop B 2004; 13:349.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/26\" class=\"nounderline abstract_t\">Spencer SA, Sorger J. Orthopedic issues in vascular anomalies. Semin Pediatr Surg 2014; 23:227.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/27\" class=\"nounderline abstract_t\">Lee A, Driscoll D, Gloviczki P, et al. Evaluation and management of pain in patients with Klippel-Trenaunay syndrome: a review. Pediatrics 2005; 115:744.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/28\" class=\"nounderline abstract_t\">Baskerville PA, Ackroyd JS, Lea Thomas M, Browse NL. The Klippel-Trenaunay syndrome: clinical, radiological and haemodynamic features and management. Br J Surg 1985; 72:232.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/29\" class=\"nounderline abstract_t\">North PE. Pediatric Vascular Tumors and Malformations. Surg Pathol Clin 2010; 3:455.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/30\" class=\"nounderline abstract_t\">Oduber CE, Young-Afat DA, van der Wal AC, et al. The persistent embryonic vein in Klippel-Trenaunay syndrome. Vasc Med 2013; 18:185.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/31\" class=\"nounderline abstract_t\">Flors L, Leiva-Salinas C, Maged IM, et al. MR imaging of soft-tissue vascular malformations: diagnosis, classification, and therapy follow-up. Radiographics 2011; 31:1321.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/32\" class=\"nounderline abstract_t\">Kanterman RY, Witt PD, Hsieh PS, Picus D. Klippel-Trenaunay syndrome: imaging findings and percutaneous intervention. AJR Am J Roentgenol 1996; 167:989.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/33\" class=\"nounderline abstract_t\">Sabharwal S, Kumar A. Methods for assessing leg length discrepancy. Clin Orthop Relat Res 2008; 466:2910.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/34\" class=\"nounderline abstract_t\">Martin JR, Pels SG, Paidas M, Seli E. Assisted reproduction in a patient with Klippel-Trenaunay syndrome: management of thrombophilia and consumptive coagulopathy. J Assist Reprod Genet 2011; 28:217.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/35\" class=\"nounderline abstract_t\">Siegel DH, Cottrell CE, Streicher JL, et al. Analyzing the Genetic Spectrum of Vascular Anomalies with Overgrowth via&nbsp;Cancer Genomics. J Invest Dermatol 2018; 138:957.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/36\" class=\"nounderline abstract_t\">Couto JA, Ayturk UM, Konczyk DJ, et al. A somatic GNA11 mutation is associated with extremity capillary malformation and overgrowth. Angiogenesis 2017; 20:303.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/37\" class=\"nounderline abstract_t\">Liu KX, Prajapati VH, Liang MG, et al. A cross-sectional survey of long-term outcomes for patients with diffuse capillary malformation with overgrowth. J Am Acad Dermatol 2017.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/38\" class=\"nounderline abstract_t\">Hershkovitz D, Bergman R, Sprecher E. A novel mutation in RASA1 causes capillary malformation and limb enlargement. Arch Dermatol Res 2008; 300:385.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/39\" class=\"nounderline abstract_t\">Oduber CE, van der Horst CM, Hennekam RC. Klippel-Trenaunay syndrome: diagnostic criteria and hypothesis on etiology. Ann Plast Surg 2008; 60:217.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/40\" class=\"nounderline abstract_t\">Mart&iacute;nez-Glez V, Romanelli V, Mori MA, et al. Macrocephaly-capillary malformation: Analysis of 13 patients and review of the diagnostic criteria. Am J Med Genet A 2010; 152A:3101.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/41\" class=\"nounderline abstract_t\">Alomari AI. Comments on the diagnosis and management of CLOVES syndrome. Pediatr Dermatol 2011; 28:215.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/42\" class=\"nounderline abstract_t\">Alomari AI, Chaudry G, Rodesch G, et al. Complex spinal-paraspinal fast-flow lesions in CLOVES syndrome: analysis of clinical and imaging findings in 6 patients. AJNR Am J Neuroradiol 2011; 32:1812.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/43\" class=\"nounderline abstract_t\">Lindhurst MJ, Sapp JC, Teer JK, et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med 2011; 365:611.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/44\" class=\"nounderline abstract_t\">Nguyen D, Turner JT, Olsen C, et al. Cutaneous manifestations of proteus syndrome: correlations with general clinical severity. Arch Dermatol 2004; 140:947.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/45\" class=\"nounderline abstract_t\">Gorlin RJ, Cohen MM Jr, Condon LM, Burke BA. Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet 1992; 44:307.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/46\" class=\"nounderline abstract_t\">Gloviczki P, Driscoll DJ. Klippel-Trenaunay syndrome: current management. Phlebology 2007; 22:291.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/47\" class=\"nounderline abstract_t\">Clericuzio CL, Martin RA. Diagnostic criteria and tumor screening for individuals with isolated hemihyperplasia. Genet Med 2009; 11:220.</a></li><li class=\"breakAll\">www-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu/books/NBK153722/ (Accessed on May 27, 2016).</li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/49\" class=\"nounderline abstract_t\">Greene AK, Kieran M, Burrows PE, et al. Wilms tumor screening is unnecessary in Klippel-Trenaunay syndrome. Pediatrics 2004; 113:e326.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/50\" class=\"nounderline abstract_t\">Peterman CM, Vadeboncoeur S, Mulliken JB, et al. Wilms tumor screening in diffuse capillary malformation with overgrowth and macrocephaly-capillary malformation: A retrospective study. J Am Acad Dermatol 2017; 77:874.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/51\" class=\"nounderline abstract_t\">Nguyen JT, Koerper MA, Hess CP, et al. Aspirin therapy in venous malformation: a retrospective cohort study of benefits, side effects, and patient experiences. Pediatr Dermatol 2014; 31:556.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/52\" class=\"nounderline abstract_t\">Bird LM, Jones MC, Kuppermann N, Huskins WC. Gram-negative bacteremia in four patients with Klippel-Trenaunay-Weber syndrome. Pediatrics 1996; 97:739.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/53\" class=\"nounderline abstract_t\">Hammill AM, Wentzel M, Gupta A, et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 2011; 57:1018.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/54\" class=\"nounderline abstract_t\">Lackner H, Karastaneva A, Schwinger W, et al. Sirolimus for the treatment of children with various complicated vascular anomalies. Eur J Pediatr 2015; 174:1579.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/55\" class=\"nounderline abstract_t\">Vlahovic AM, Vlahovic NS, Haxhija EQ. Sirolimus for the Treatment of a Massive Capillary-Lymphatico-Venous Malformation: A Case Report. Pediatrics 2015; 136:e513.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/56\" class=\"nounderline abstract_t\">Yesil S, Tanyildiz HG, Bozkurt C, et al. Single-center experience with sirolimus therapy for vascular malformations. Pediatr Hematol Oncol 2016; 33:219.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/57\" class=\"nounderline abstract_t\">Triana P, Dore M, Cerezo VN, et al. Sirolimus in the Treatment of Vascular Anomalies. Eur J Pediatr Surg 2017; 27:86.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/58\" class=\"nounderline abstract_t\">Bessis D, Vernhet H, Bigorre M, et al. Life-Threatening Cutaneous Bleeding in Childhood Klippel-Trenaunay Syndrome Treated With Oral Sirolimus. JAMA Dermatol 2016; 152:1058.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/59\" class=\"nounderline abstract_t\">Boscolo E, Limaye N, Huang L, et al. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects. J Clin Invest 2015; 125:3491.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/60\" class=\"nounderline abstract_t\">Adams DM, Trenor CC 3rd, Hammill AM, et al. Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. Pediatrics 2016; 137:e20153257.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/61\" class=\"nounderline abstract_t\">Sermsathanasawadi N, Hongku K, Wongwanit C, et al. Endovenous radiofrequency thermal ablation and ultrasound-guided foam sclerotherapy in treatment of klippel-trenaunay syndrome. Ann Vasc Dis 2014; 7:52.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/62\" class=\"nounderline abstract_t\">Gloviczki P, Stanson AW, Stickler GB, et al. Klippel-Trenaunay syndrome: the risks and benefits of vascular interventions. Surgery 1991; 110:469.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/63\" class=\"nounderline abstract_t\">Burrows PE, Mason KP. Percutaneous treatment of low flow vascular malformations. J Vasc Interv Radiol 2004; 15:431.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/64\" class=\"nounderline abstract_t\">Malgor RD, Gloviczki P, Fahrni J, et al. Surgical treatment of varicose veins and venous malformations in Klippel-Trenaunay syndrome. Phlebology 2016; 31:209.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/65\" class=\"nounderline abstract_t\">Husmann DA, Rathburn SR, Driscoll DJ. Klippel-Trenaunay syndrome: incidence and treatment of genitourinary sequelae. J Urol 2007; 177:1244.</a></li><li><a href=\"https://www.uptodate.com/contents/klippel-trenaunay-syndrome-clinical-manifestations-diagnosis-and-management/abstract/66\" class=\"nounderline abstract_t\">Samo S, Sherid M, Husein H, et al. Klippel-Trenaunay Syndrome Causing Life-Threatening GI Bleeding: A Case Report and Review of the Literature. Case Rep Gastrointest Med 2013; 2013:813653.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 13730 Version 5.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H3228166582\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H738068296\" id=\"outline-link-H738068296\">INTRODUCTION</a></li><li><a href=\"#H3425593432\" id=\"outline-link-H3425593432\">EPIDEMIOLOGY</a></li><li><a href=\"#H3968521269\" id=\"outline-link-H3968521269\">CLASSIFICATION</a></li><li><a href=\"#H2839404764\" id=\"outline-link-H2839404764\">PATHOGENESIS</a></li><li><a href=\"#H3383733452\" id=\"outline-link-H3383733452\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H3037764232\" id=\"outline-link-H3037764232\">Capillary malformation</a></li><li><a href=\"#H3542307160\" id=\"outline-link-H3542307160\">Venous malformation</a></li><li><a href=\"#H3788216779\" id=\"outline-link-H3788216779\">Lymphatic malformation</a></li><li><a href=\"#H2422825182\" id=\"outline-link-H2422825182\">Overgrowth</a></li><li><a href=\"#H1878193818\" id=\"outline-link-H1878193818\">Complications</a><ul><li><a href=\"#H1656106299\" id=\"outline-link-H1656106299\">- Clotting disorders and thromboembolism</a></li><li><a href=\"#H4003071386\" id=\"outline-link-H4003071386\">- Bleeding</a></li><li><a href=\"#H1995292914\" id=\"outline-link-H1995292914\">- Limb length discrepancy</a></li><li><a href=\"#H3555335840\" id=\"outline-link-H3555335840\">- Chronic lymphedema/venous insufficiency</a></li><li><a href=\"#H3997896703\" id=\"outline-link-H3997896703\">- Cellulitis</a></li><li><a href=\"#H849909441\" id=\"outline-link-H849909441\">- Pain</a></li></ul></li></ul></li><li><a href=\"#H826863360\" id=\"outline-link-H826863360\">PATHOLOGY</a></li><li><a href=\"#H2952888392\" id=\"outline-link-H2952888392\">DIAGNOSIS</a><ul><li><a href=\"#H1885598182\" id=\"outline-link-H1885598182\">Imaging studies</a><ul><li><a href=\"#H277152775\" id=\"outline-link-H277152775\">- Ultrasonography</a></li><li><a href=\"#H46352013\" id=\"outline-link-H46352013\">- Magnetic resonance imaging</a></li><li><a href=\"#H3378638044\" id=\"outline-link-H3378638044\">- Conventional venography</a></li><li><a href=\"#H2222240455\" id=\"outline-link-H2222240455\">- Plain radiograph</a></li></ul></li><li><a href=\"#H3199488687\" id=\"outline-link-H3199488687\">Laboratory studies</a></li><li><a href=\"#H2180466713\" id=\"outline-link-H2180466713\">Biopsy</a></li></ul></li><li><a href=\"#H620490315\" id=\"outline-link-H620490315\">DIFFERENTIAL DIAGNOSIS</a><ul><li><a href=\"#H3937083077\" id=\"outline-link-H3937083077\">Capillary malformation</a></li><li><a href=\"#H3248521004\" id=\"outline-link-H3248521004\">Diffuse capillary malformation with overgrowth</a></li><li><a href=\"#H3310890272\" id=\"outline-link-H3310890272\">Parkes Weber syndrome</a></li><li><a href=\"#H274756352\" id=\"outline-link-H274756352\">Servelle-Martorell syndrome</a></li><li><a href=\"#H3124645245\" id=\"outline-link-H3124645245\">Macrocephaly-capillary malformation</a></li><li><a href=\"#H516434826\" id=\"outline-link-H516434826\">CLOVES syndrome</a></li><li><a href=\"#H3183845736\" id=\"outline-link-H3183845736\">Proteus syndrome/PTEN hamartoma tumor syndrome</a></li></ul></li><li><a href=\"#H3052860088\" id=\"outline-link-H3052860088\">MANAGEMENT</a><ul><li><a href=\"#H3525030370\" id=\"outline-link-H3525030370\">Supportive treatment and surveillance</a></li><li><a href=\"#H3998823637\" id=\"outline-link-H3998823637\">Management of leg length discrepancy</a></li><li><a href=\"#H3004682947\" id=\"outline-link-H3004682947\">Medical treatment</a><ul><li><a href=\"#H3052945077\" id=\"outline-link-H3052945077\">- Chronic coagulopathy</a></li><li><a href=\"#H1361017158\" id=\"outline-link-H1361017158\">- Infection</a></li><li><a href=\"#H113413074\" id=\"outline-link-H113413074\">- Pain control</a></li><li><a href=\"#H2831547210\" id=\"outline-link-H2831547210\">- mTOR inhibitors</a></li></ul></li><li><a href=\"#H3744279357\" id=\"outline-link-H3744279357\">Surgical therapies</a></li></ul></li><li><a href=\"#H2755843852\" id=\"outline-link-H2755843852\">PROGNOSIS</a></li><li><a href=\"#H3228166582\" id=\"outline-link-H3228166582\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/13730|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/108942\" class=\"graphic graphic_diagnosticimage\">- Klippel-Trenaunay MRI</a></li></ul></li><li><div id=\"DERM/13730|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/108288\" class=\"graphic graphic_picture\">- Klippel-Trenaunay 1</a></li><li><a href=\"image.htm?imageKey=DERM/108289\" class=\"graphic graphic_picture\">- Klippel-Trenaunay 2</a></li><li><a href=\"image.htm?imageKey=DERM/108290\" class=\"graphic graphic_picture\">- Klippel-Trenaunay 3</a></li><li><a href=\"image.htm?imageKey=DERM/108305\" class=\"graphic graphic_picture\">- Diffuse capillary malformation with overgrowth</a></li><li><a href=\"image.htm?imageKey=ONC/73826\" class=\"graphic graphic_picture\">- Cerebriform connective tissue nevus plantar foot</a></li></ul></li><li><div id=\"DERM/13730|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/108302\" class=\"graphic graphic_table\">- Klippel-Trenaunay differential diagnosis</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-magnetic-resonance-imaging-and-computed-tomography-procedures\" class=\"medical medical_review\">Anesthesia for magnetic resonance imaging and computed tomography procedures</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=beckwith-wiedemann-syndrome\" class=\"medical medical_review\">Beckwith-Wiedemann syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=capillary-malformations-port-wine-stains-and-associated-syndromes\" class=\"medical medical_review\">Capillary malformations (port wine stains) and associated syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cellulitis-and-skin-abscess-in-adults-treatment\" class=\"medical medical_review\">Cellulitis and skin abscess in adults: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cellulitis-and-skin-abscess-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Cellulitis and skin abscess: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-the-nonpregnant-adult-with-suspected-deep-vein-thrombosis-of-the-lower-extremity\" class=\"medical medical_review\">Clinical presentation and diagnosis of the nonpregnant adult with suspected deep vein thrombosis of the lower extremity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-staging-and-conservative-management-of-peripheral-lymphedema\" class=\"medical medical_review\">Clinical staging and conservative management of peripheral lymphedema</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=direct-oral-anticoagulants-and-parenteral-direct-thrombin-inhibitors-dosing-and-adverse-effects\" class=\"medical medical_review\">Direct oral anticoagulants and parenteral direct thrombin inhibitors: Dosing and adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=endovenous-laser-ablation-for-the-treatment-of-lower-extremity-chronic-venous-disease\" class=\"medical medical_review\">Endovenous laser ablation for the treatment of lower extremity chronic venous disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=laser-and-light-therapy-for-cutaneous-vascular-lesions\" class=\"medical medical_review\">Laser and light therapy for cutaneous vascular lesions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=liquid-foam-and-glue-sclerotherapy-techniques-for-the-treatment-of-lower-extremity-veins\" class=\"medical medical_review\">Liquid, foam, and glue sclerotherapy techniques for the treatment of lower extremity veins</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=open-surgical-techniques-for-lower-extremity-vein-ablation\" class=\"medical medical_review\">Open surgical techniques for lower extremity vein ablation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pten-hamartoma-tumor-syndrome-including-cowden-syndrome\" class=\"medical medical_review\">PTEN hamartoma tumor syndrome, including Cowden syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=stasis-dermatitis\" class=\"medical medical_review\">Stasis dermatitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vascular-lesions-in-the-newborn\" class=\"medical medical_review\">Vascular lesions in the newborn</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=venous-thromboembolism-anticoagulation-after-initial-management\" class=\"medical medical_review\">Venous thromboembolism: Anticoagulation after initial management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=venous-thrombosis-and-thromboembolism-in-children-treatment-prevention-and-outcome\" class=\"medical medical_review\">Venous thrombosis and thromboembolism in children: Treatment, prevention, and outcome</a></li></ul></div></div>","javascript":null}